Clinical trial
Study of the Safety and Effectiveness of Esmirtazapine in Participants With…
NCT00482612 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00482612 |
|---|---|
| Title | Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706) |
| Official title | A Two-Week, Double Blind, Placebo-Controlled, Randomized, Parallel Group, Efficacy and Safety Out-Patient Trial With Org 50081 in Patients With Chronic Primary Insomnia |
| Acronym | RUBY |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Insomnia |
| Intervention type | Drug |
| Interventions | Esmirtazapine, Placebo |
| Enrollment | 526 |
| Start date | Dec 7, 2006 |
| Primary completion | Aug 11, 2008 |
| Completion | Aug 11, 2008 |
| First posted | Jun 5, 2007 |
| Last update posted | Oct 3, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: